civorebrutinib (EVER-001) / SinoMab, Everest Medicines, Evopoint, Travere Therap - LARVOL DELTA

Everest Medicines Announces Interim Results for First Half of 2026 (Everest Medicines Press Release) - "In June 2026, Everest entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc...for the development and commercialization of civorebrutinib (EVER001) outside China and certain countries in East and Southeast Asia. The collaboration is intended to accelerate the global development and potential commercialization of civorebrutinib across multiple immune-mediated kidney diseases, including primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)."

Licensing / partnership • Focal Segmental Glomerulosclerosis • Immunology • Nephrology

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 (clinicaltrials.gov) - P1 | N=31 | Completed | Sponsor: Everest Medicines (China) Co.,Ltd. | Recruiting ➔ Completed

Trial completion • Glomerulonephritis • Renal Disease

Bruton's Tyrosine Kinase Inhibitor EVER001 in Chinese Patients With Primary Membranous Nephropathy: Preliminary Results From a Phase 1b/2a Study (ERA 2026) - P1 | "Conclusion In this preliminary analysis, EVER001 was generally well tolerated and was associated with marked reduction in anti-PLA2R and proteinuria, supporting its potential as a treatment for pMN and other proteinuric autoimmune glomerular diseases. Image"

Clinical • P1/2 data • Glomerulonephritis • Hematological Disorders • Immunology • Infectious Disease • Renal Disease • Respiratory Diseases

Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases (clinicaltrials.gov) - P2 | N=45 | Recruiting | Sponsor: Everest Medicines (China) Co.,Ltd.

New P2 trial • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Renal Disease

Novel Bruton's Tyrosine Kinase Inhibitor EVER001 in Chinese Patients With Primary Membranous Nephropathy: Preliminary Results From a Phase 1b/2a Study (ERA 2025) - P1 | "Preliminary results showed that EVER001 was well tolerated and effective in patients with pMN, supporting its potential as a treatment for proteinuric autoimmune glomerular diseases."

Clinical • P1/2 data • Anemia • Glomerulonephritis • Hematological Disorders • Immunology • Infectious Disease • Renal Disease • Respiratory Diseases

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Everest Medicines (China) Co.,Ltd. | Trial completion date: Apr 2026 ➔ Sep 2026 | Trial primary completion date: Jan 2026 ➔ Sep 2026

Trial completion date • Trial primary completion date • Glomerulonephritis • Renal Disease

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Everest Medicines (China) Co.,Ltd. | Not yet recruiting ➔ Recruiting | Phase classification: P1b/2 ➔ P1

Enrollment open • Phase classification • Glomerulonephritis • Renal Disease

A randomised, controlled single and multiple ascending dose trial of the safety, pharmacokinetics and pharmacodynamics of SN1011 in healthy subjects. (PubMed, Clin Transl Sci) - "BTK receptor occupancy remained above 83% over 24 h after single administration and remained above 80% for the MAD groups for 10 days of continuous QD administration. SN1011 was well tolerated and safe after single or multiple exposures to healthy subjects, supporting further clinical development of SN1011 for treatment of autoimmune diseases."

Journal • PK/PD data • Immunology